UniCredit Call 180 ABBV 18.09.202.../ DE000HD03JQ5 /
| 2024-05-03 2:21:01 PM | Chg.+0.020 | Bid4:26:25 PM | Ask4:26:25 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.240EUR | +9.09% | 0.260 Bid Size: 20,000 |
0.270 Ask Size: 20,000 |
AbbVie Inc | 180.00 USD | 2024-09-18 | Call |
GlobeNewswire
05-02
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial G...
GlobeNewswire
05-02
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer a...
GlobeNewswire
05-01
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
04-30
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings,...
GlobeNewswire
04-30
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...
GlobeNewswire
04-25
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
GlobeNewswire
04-25
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire
04-24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
04-23
Leaders from Fortune 100 Best Companies to Work For To Share Insights at For All Summit May 7-9
GlobeNewswire
04-22
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire
04-19
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes a...
GlobeNewswire
04-19
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...
GlobeNewswire
04-18
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial fo...
GlobeNewswire
04-16
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...
GlobeNewswire
04-16
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of C...
GlobeNewswire
04-16
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire
04-15
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessi...
Newsfile Corp
04-12
Allergan Aesthetics and University Lab Partners Announce the Golden Ticket Pitch Competition to Acce...
